Is Pfizer stock a buy after an FDA panel voted to recommend Covid booster shots for some people? Is PFE stock a buy now?
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting
SVB Leerink analyst Geoffrey Porges sees a silver lining from Pfizer's bumpy ride at a Food and Drug Administration advisory committee meeting about Covid-19 vaccine boosters.
On Monday, the company said the U.S. securities regulator was investigating its disclosures regarding employment matters and related issues. "There is absolutely no place anywhere in our company for discrimination, harassment, or unequal treatment of any kind," said Bobby Kotick, Activision's chief executive officer. The investigation comes at a time when Activision is embroiled in a lawsuit that alleges equal pay violations, sex discrimination and sexual harassment at the company.
- Investor's Business Daily
The Dow Jones crashed lower amid growing China fears. Nvidia stock flashed a sell signal, while Tesla stock hit the skids. Apple stock fell.
- Motley Fool
Enough money invested in a high-yielding dividend stock could provide a sizable income, which is why dividend stocks are so popular with retirees. Realty Income (NYSE: O) is one REIT that pays a high-yielding monthly dividend, and it's a great place to start.
- Investor's Business Daily
Is Moderna stock a buy after the Pfizer and BioNTech win FDA approval for their rival Covid shot? Is MRNA stock a buy right now?
- Motley Fool
A partial victory is better than a complete loss. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) are experiencing this firsthand. The two partners had hoped that a U.S. Food and Drug Administration (FDA) advisory committee would recommend COVID-19 vaccine boosters for all Americans ages 16 and up.
It’s business as usual for Microsoft (MSFT) in 2021, with the stock on an almost constant steady upward trajectory. Looking ahead, Tigress analyst Ivan Feinseth expects the good times to continue, claiming the “ongoing digital transformation, increasing cloud strength and new product introductions will continue to drive significant revenue and Economic Profit growth.” In fact, the 5-star analyst not only reiterated a Buy rating for MSFT stock but also increased the price target from $303 to $366
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.
- The Week
Pfizer and BioNTech say lower dose of COVID-19 vaccine proved safe, effective in kids 5 to 11
The S&P 500 had its worst day in months Monday, tumbling 1.7% on fears that property giant China Evergrande Group ‘s (ticker: 3333.Hong Kong) troubles may spill over into other markets. Friday, the S&P 500 fell below its 50-day moving average, a technical indicator that shows investors are losing confidence in the market outlook. The S&P 500 is 3.9% below its all-time high as of Monday’s close, at its lowest level since mid-June.
- WMUR - Manchester
Many doctors in New Hampshire are welcoming news that COVID-19 vaccines for younger children are one step closer, with Pfizer announcing Monday that it will soon seek authorization for its vaccine for use in children ages 5 to 11.
- WBAL - Baltimore Videos
Students around Maryland have returned to school and there remain many concerns among parents of children under 12 years old who are not eligible to get vaccinated against COVID-19. Now with news that Pfizer is confident its vaccine will work in younger children, doctors say now is a good time to start talking to your child's pediatrician about it. According to Pfizer, its latest clinical trials show its COVID-19 vaccine is safe and generates a "robust" immune response in children ages 5 to 11. The company used about a third of the dosage used for teens and adults.
- WABC – NY
In this episode of Up Close, we discuss the politics and controversy behind vaccine requirements for New York City public school teachers.
President Joe Biden wanted booster shots to be ready as soon as this week, pending FDA approval, because “we wanted to be ready," Fauci said.
Let's check out the charts of this company that performs a deep search of all criminal, financial, medical, communication, and clandestine agency records on the target. Aggressive traders could buy more at current levels risking to $16. Traders who bought PLTR got a rally to $28 this month but another review of things seems in order today.
- Motley Fool
If you buy high-quality companies and hang onto them for long periods of time, your chances of growing your initial investment by leaps and bounds goes up significantly. What's more, Novavax's vaccine development platform should allow it to quickly tackle new variants and develop potential combination treatments in the future.
Stop losing money on mediocre businesses.
- Motley Fool
If you're Cathie Wood, founder, and CEO of ARK Invest, you keep buying more. Shares of life-science equipment manufacturer Berkeley Lights (NASDAQ: BLI) took a hit last week, and two ARK Invest ETFs quickly bought more. Wood also bought two genomics stocks that have tanked this year, Personalis (NASDAQ: PSNL) and Invitae (NYSE: NVTA).
On Monday, this somewhat obscure, overseas risk suddenly shook up financial markets from Asia to Europe and the U.S., where all three major benchmark stock indexes, the S&P 500 (SPX) Dow industrials (DJIA) and Nasdaq Composite (COMP) appeared to be headed for the worst one-day drop in more than two months. On one level, Evergrande—which reportedly faces at least $83.5 million in interest payments due on Thursday, with a 30-day grace period — is raising concerns about a liquidity crisis among all Chinese and Hong Kong property companies, as markets quickly turn off access to dollar funding. In a more macro way, the firm’s woes are bringing to the fore China’s wide-scale regulatory crackdown across most of its businesses, starting with technology giant Alibaba Group Holding Ltd. (HK:9988) which is rattling confidence in the world’s second-largest economy.
(Bloomberg) -- A global rout in stock markets sparked by concerns over China Evergrande Group hit the world’s biggest fortunes Monday, with the richest 500 people losing a combined $135 billion.Most Read from BloombergThe Global Housing Market Is Broken, and It’s Dividing Entire CountriesMerkel’s Legacy Comes to Life on Berlin’s ‘Arab Street’Is There Room for E-Scooters in New York City?Istanbul Turns Taps on Old Fountains, Joining Global Push for Free DrinksAmazon, Microsoft Swoop In on $24 Bil